TristelTSNLF +6.35%97 Net Margin % is 15.42% as of Dec. 2025, which is 6% above its 10-year median of 14.51. GuruFocus rates TSNLF with a GF Score™ of 97/100 and a GF Value™ of $6.13 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 817 Medical Devices & Instruments companies, Tristel ranks better than 83.6% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Tristel's Net Income for the
six
months ended in Dec. 2025 was $5.29 Mil. Tristel's Revenue for the
six
months ended in Dec. 2025 was $34.34 Mil. Therefore, Tristel's net margin for the quarter that ended in Dec. 2025 was 15.42%.
The historical rank and industry rank for Tristel's Net Margin % or its related term are showing as below:
TSNLF'
s Net Margin % Range Over the Past 10 Years
Min: 3.17 Med: 14.51 Max: 16.85
Current: 15.88
TSNLF's Net Margin % is ranked better than 83.6% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.07
vs TSNLF: 15.88
Tristel (OTCPK:TSNLF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Tristel Net Margin % Related Terms
Tristel Net Margin % Historical Data
* Premium members only.
The historical data trend for Tristel's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Tristel's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tristel Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tristel's Net Margin % distribution charts can be found below:
* The bar in red indicates where Tristel's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tristel (TSNLF) has a Net Margin % of 15.42% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Tristel and its competitors. This is near median its historical median of 14.51. Over the past decade, Tristel's Net Margin % has ranged from 3.17 to 16.85. According to the industry distribution chart, Tristel ranks #134 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 16.4%.
Is Tristel's Net Margin % too high?
Tristel's current Net Margin % of 15.42% is near median its 10-year median of 14.51. Over the past 10 years, this metric has ranged from a low of 3.17 to a high of 16.85. The Medical Devices & Instruments industry median Net Margin % is 2.07. Tristel's value of 15.42% is 644.9% above this industry median. Based on the distribution chart, Tristel ranks #134 out of 817 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tristel has a GF Score™ of 97/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tristel's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tristel ranks #134 out of 817 companies for Net Margin %. This places Tristel in the top 16% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.07. Tristel's value of 15.42% is 644.9% above this benchmark. Historically, Tristel's own Net Margin % has ranged from 3.17 to 16.85 over the past decade. While the company's 10-year median is 14.51 vs. the industry median of 2.07, Tristel has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.07, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tristel's current Net Margin % of 15.42% is 644.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Tristel and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tristel's current Net Margin % is 15.42%, which is near median its own 10-year median of 14.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tristel stock overvalued right now?
Based on GuruFocus' analysis, Tristel (TSNLF) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.13, compared to a current price of $5.53 — trading 9.8% below its estimated fair value. The current Net Margin % is 15.42%, which is near median its 10-year median of 14.51 and 644.9% above the Medical Devices & Instruments industry median of 2.07. Tristel's overall GF Score™ is 97/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Tristel (TSNLF), the current Net Margin % is 15.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tristel (TSNLF) Overvalued in 2026?
Based on GuruFocus' analysis, Tristel stock appears to be undervalued.
The current stock price of $5.53 is trading 9.8% below its estimated GF Value™ of $6.13.
GuruFocus considers Tristel to be Modestly Undervalued.
Key valuation signals for TSNLF:
Net Margin %: 15.42% (near median its 10-year median of 14.51)
GF Value™: $6.13 vs. price of $5.53 (9.8% below fair value)
Industry Position: 644.9% above the Medical Devices & Instruments median (#134 of 817)
No single metric tells the full story. See the TSNLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tristel PLC's business is the sale to hospitals of its proprietary chlorine dioxide chemistry used for the decontamination of medical devices under the Tristel brand and for the sporicidal disinfection of environmental surfaces under the Cache brand. Its operating segments include hospital medical device decontamination products used predominantly for infection control in hospitals; the manufacture and sale of hospital environmental surface disinfection products; and pharmaceutical and personal care product manufacturing industries, veterinary and animal welfare. The company generates the majority of its revenue from hospital medical device decontamination and operates geographically in the UK and overseas markets.
97GF Score
Get the complete analysis for TSNLF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSNLF has been successfully added to your 
